South Korean biotech firm Oscotec Co. reported consolidated revenue of 99.84 billion won and operating income of 52.08 billion won for 2025, the company announced on the 27th. Revenue surged 193.5% from 34.01 billion won in 2024, while operating profit returned to black.
Revenue included milestone payments from the March and July commercialization in Japan and China of Yuhan Corporation's EGFR-mutant non-small cell lung cancer drug Leclaza (lazertinib) in combination with Janssen's Rybrevant (amivantamab), as well as royalties from expanded domestic and international prescriptions. Oscotec is the original developer of Leclaza.
An upfront payment received from global healthcare company Sanofi for the technology transfer of ADEL-Y01, an Alzheimer's disease drug candidate targeting tau protein, was also reflected in last year's revenue.
Oscotec plans to establish a "Dual-Hub Model" with its U.S. subsidiary Genosco, maximizing cost and operational efficiency through integrated operations while maintaining each entity's expertise. The company said it is strengthening competitiveness with "anti-resistance cancer therapeutics" that fundamentally block drug resistance as a core mid-to-long-term R&D pipeline.
"We are seeking external partnerships to develop our existing legacy pipeline into patient-tailored innovative drugs without additional internal investment," said Yoon Tae-young, CEO of Oscotec.
